All In Biotech

Drug Trial Radar · NCT01238861

Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults With Uncontrolled Asthma

A Phase 2b, Dose-ranging Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults With Uncontrolled Asthma

Last checked: Nov 20, 2026Latest source record: Nov 17, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 964 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

964

Actual

Start

Dec 2010

Primary completion

Mar 2013

Study completion Aug 2013

Sponsor

Lead sponsor
MedImmune LLCAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
MedImmune Ltd
First posted
Nov 11, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to evaluate the effect of multiple-dose subcutaneous administrations of MEDI-563 on adults with uncontrolled asthma.

Conditions

  • Asthma

Interventions

  • Benralizumab 2 mgBiological

    EOS+ participants received single benralizumab 2 milligram (mg) injection followed by a single placebo injection subcutaneously.

  • Benralizumab 20 mgBiological

    EOS+ participants received single benralizumab 20 mg injection followed by a single placebo injection subcutaneously.

  • Benralizumab 100 mgBiological

    EOS+ and EOS- participants received two benralizumab 50 mg injections subcutaneously.

  • PlaceboOther

    EOS+ and EOS- participants received two placebo injections subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annual Asthma Exacerbation Rate (AER) for Eosinophilic Phenotype (EOS+) ParticipantsTime frame: Week 1 up to Week 52

Locations

74 sites in 10 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Los Angeles, California

  • Research Site

    Orange, California

  • Research Site

    San Diego, California

  • Research Site

    Stockton, California

  • Research Site

    Colorado Springs, Colorado

  • Research Site

    Denver, Colorado

  • Research Site

    Waterbury, Connecticut

  • Research Site

    Kissimmee, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    Stockbridge, Georgia

  • Research Site

    Normal, Illinois

  • Research Site

    Baltimore, Maryland

  • Research Site

    Rochester, Minnesota

  • Research Site

    St Louis, Missouri

  • Research Site

    Bellevue, Nebraska

  • Research Site

    Summit, New Jersey

  • Research Site

    Rochester, New York

  • Research Site

    Winston-Salem, North Carolina

  • Research Site

    Cincinnati, Ohio

  • Research Site

    Oklahoma City, Oklahoma

  • Research Site

    Blue Bell, Pennsylvania

  • Research Site

    Pittsburgh, Pennsylvania

  • Research Site

    Warwick, Rhode Island

  • Research Site

    Boerne, Texas

  • Research Site

    San Antonio, Texas

  • Research Site

    Seattle, Washington

  • Research Site

    Caba, Argentina

  • Research Site

    Ciudad de Buenos Aires, Argentina

  • Research Site

    San Miguel de Tucumán, Argentina

  • Research Site

    Santa Fe, Argentina

  • Research Site

    Curitiba, Brazil

  • Research Site

    Florianópolis, Brazil

  • Research Site

    Juiz de Fora, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Rio de Janeiro, Brazil

  • Research Site

    Salvador, Brazil

  • Research Site

    Santo André, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    Pleven, Bulgaria

Showing 40 of 74 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.